Sorrento Therapeutics Inc (SRNE)

[dia76ca]

The acquisition of SmartPharm will advance Sorrento's Covid and cancer programs. However SmartPharm also has been doing preclinical research into restoring heart tissue following heart attacks. Heart attacks (also called acute myocardial infarction or AMI) occur over 7 million times a year worldwide . Standard procedures following an AMI are stenting or grafting but they don't restore damaged tissue. Here is where SmartPharms technology comes in.
"While procedures for AMI are capable of restoring blood flow to the areas of the heart affected by the blockage, they do not address the restoration of the damaged tissue. While a certain portion of the heart tissue dies after AMI, a greater portion is in a state of stress. Following AMI, significant portions of this tissue may eventually die, leading to a significant loss of heart function. The result is a decrease in cardiovascular performance, which may eventually lead to heart failure. One in four patients develops heart failure within four years of AMI. This is a debilitating medical condition with very high medical and non-medical costs. In other patients, arrythmias may develop.

SmartPharm Therapeutics is developing treatments to ameliorate the damage caused by heart attacks on the cardiac tissue. These are designed to be used with the major procedures for treating AMI." Sorrento may have yet another blockbuster program area on its hands!